Perphenazine

Perphenazine is a first-generation (typical) antipsychotic of the phenothiazine class, specifically a piperazinyl phenothiazine derivative. It is primarily used to treat schizophrenia and to control severe nausea and vomiting in adults. Perphenazine acts mainly by antagonizing dopamine D1 and D2 receptors in the brain, thereby reducing abnormal excitement and psychotic symptoms. Its antiemetic effect is largely due to dopamine D2 receptor blockade in the chemoreceptor trigger zone and vomiting center. Perphenazine also binds alpha-adrenergic receptor, with additional effects on histamine- and serotonin-mediated pathways[1][3][6]. The drug has been available for decades, originally marketed under the brand name Trilafon[8].

Brand names

Trilafon

Other names

perphenazine decanoate